Here's an article from Forbes on this new drug.

Bad News: Merck Withdraws Arcoxia Application
Matthew Herper, 03.15.02, 2:00 PM ET

NEW YORK - Merck today withdrew its application with the Food and Drug Administration for Arcoxia, its next-generation painkiller. Many analysts had been expecting the drug to help Merck win a long-standing duel for the arthritis market with rival Pharmacia, which makes similar drugs.

http://www.forbes.com/2002/03/15/0315mrk.html

One major issue, Butler says, is whether the drug would be approved to treat any form of chronic pain. Such an approval is essential for Arcoxia to beat Pharmacia's drugs. Merck's stated reason for withdrawing the application is that it wants a chronic-pain indication. The company says new data could result in Arcoxia being approved for a form of chronic back pain called ankylosing spondylitis.

BEWARE, IT'S ALWAYS ABOUT THE MONEY!
THERE'S A LINK ON THE ABOVE URL TO ANOTHER FORBES ARTICLE ABOUT NOVARTIS' NEW ARTHRITIS DRUG...COX-189



Rowr



"Rumors of my death are greatly exaggerated."Mark Twain


"Rumors of my death are greatly exaggerated."Mark Twain